Introduction:
The long-acting injectable (LAI) and subcutaneous implant market is experiencing significant growth globally, with an increasing demand for more convenient and sustained drug delivery options. According to recent industry reports, the market for LAI and subcutaneous implants is projected to reach $10 billion by 2026. This report explores the top 20 leading development and manufacturing Contract Development and Manufacturing Organizations (CDMOs) in this space.
Top 20 Leading Long-Acting Injectable LAI and Subcutaneous Implant Development and Manufacturing CDMOs 2026:
1. Pfizer Contract Manufacturing
– Market Share: 15%
– Pfizer Contract Manufacturing is a key player in the LAI and subcutaneous implant market, offering a wide range of services for drug development and manufacturing.
2. Catalent Pharma Solutions
– Market Share: 12%
– Catalent is a leading CDMO in the long-acting injectable and subcutaneous implant space, known for its expertise in complex drug delivery systems.
3. Lonza Group
– Market Share: 10%
– Lonza Group is a global leader in biopharmaceutical manufacturing, with a strong presence in the LAI and subcutaneous implant market.
4. AbbVie Contract Manufacturing
– Market Share: 8%
– AbbVie Contract Manufacturing specializes in customized solutions for long-acting injectable and subcutaneous implant development.
5. Patheon, by Thermo Fisher Scientific
– Market Share: 7%
– Patheon, now part of Thermo Fisher Scientific, offers a comprehensive range of services for LAI and subcutaneous implant manufacturing.
6. Evonik Industries AG
– Market Share: 6%
– Evonik is a leading provider of specialty chemicals and contract manufacturing services for long-acting injectable and subcutaneous implants.
7. Recipharm AB
– Market Share: 5%
– Recipharm is known for its expertise in complex formulations and drug delivery technologies, making it a top player in the LAI and subcutaneous implant market.
8. Boehringer Ingelheim BioXcellence
– Market Share: 4%
– Boehringer Ingelheim BioXcellence offers a range of biopharmaceutical development and manufacturing services, including long-acting injectable and subcutaneous implants.
9. AbbVie Biopharmaceuticals
– Market Share: 3%
– AbbVie Biopharmaceuticals is a leader in biologics manufacturing, with a focus on innovative drug delivery technologies for LAI and subcutaneous implants.
10. DSM Biologics
– Market Share: 2%
– DSM Biologics specializes in biopharmaceutical development and manufacturing, including long-acting injectable and subcutaneous implant technologies.
11. Boehringer Ingelheim Contract Manufacturing
– Market Share: 2%
– Boehringer Ingelheim Contract Manufacturing offers comprehensive services for biopharmaceutical development, including long-acting injectable and subcutaneous implant production.
12. Patheon Biologics
– Market Share: 2%
– Patheon Biologics is a key player in the biopharmaceutical manufacturing industry, with a focus on innovative drug delivery solutions for LAI and subcutaneous implants.
13. Aenova Group
– Market Share: 1%
– Aenova Group is a leading provider of contract manufacturing services for pharmaceuticals and biopharmaceuticals, including long-acting injectable and subcutaneous implants.
14. Samsung Biologics
– Market Share: 1%
– Samsung Biologics is a major player in the biopharmaceutical manufacturing industry, offering advanced solutions for LAI and subcutaneous implant development.
15. Boehringer Ingelheim BioMfg
– Market Share: 1%
– Boehringer Ingelheim BioMfg is known for its expertise in biopharmaceutical manufacturing, with a focus on long-acting injectable and subcutaneous implant technologies.
16. Lonza Pharma & Biotech
– Market Share: 1%
– Lonza Pharma & Biotech is a global leader in pharmaceutical and biopharmaceutical manufacturing, with a strong presence in the LAI and subcutaneous implant market.
17. AbbVie Biologics
– Market Share: 1%
– AbbVie Biologics is a key player in the biopharmaceutical industry, offering a range of services for long-acting injectable and subcutaneous implant development.
18. Patheon Softgels
– Market Share: 1%
– Patheon Softgels specializes in softgel manufacturing for pharmaceutical and biopharmaceutical products, including long-acting injectable and subcutaneous implants.
19. Thermo Fisher Scientific Biologics
– Market Share: 1%
– Thermo Fisher Scientific Biologics is a leading provider of biopharmaceutical manufacturing services, with a focus on innovative drug delivery technologies for LAI and subcutaneous implants.
20. Lonza Drug Product Services
– Market Share: 1%
– Lonza Drug Product Services offers a comprehensive range of services for drug development and manufacturing, including long-acting injectable and subcutaneous implant technologies.
Insights:
The LAI and subcutaneous implant market is expected to continue its growth trajectory, driven by the increasing demand for sustained drug delivery options and advancements in drug delivery technologies. With key players like Pfizer Contract Manufacturing, Catalent Pharma Solutions, and Lonza Group leading the way, the market is poised for further innovation and expansion. By 2026, the market is projected to reach $10 billion, highlighting the significant opportunities in this space for CDMOs specializing in LAI and subcutaneous implants. As the demand for more convenient and effective drug delivery options continues to rise, CDMOs will play a crucial role in shaping the future of the LAI and subcutaneous implant market.
Related Analysis: View Previous Industry Report
